Anavex Life Sciences Corp.
AVXL
$9.53
-$0.02-0.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.77% | -0.71% | 1.77% | -7.16% | -17.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.32% | 11.33% | 7.87% | -4.50% | -11.47% |
| Operating Income | -9.32% | -11.33% | -7.87% | 4.50% | 11.47% |
| Income Before Tax | -16.11% | -16.37% | -8.09% | 9.20% | 19.03% |
| Income Tax Expenses | -93.75% | -439.13% | -559.26% | -1,871.43% | -122.79% |
| Earnings from Continuing Operations | -15.99% | -16.13% | -7.73% | 9.48% | 19.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.99% | -16.13% | -7.73% | 9.48% | 19.60% |
| EBIT | -9.32% | -11.33% | -7.87% | 4.50% | 11.47% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.03% | -12.03% | -3.08% | 13.85% | 23.81% |
| Normalized Basic EPS | -13.04% | -12.15% | -5.56% | 11.97% | 21.89% |
| EPS Diluted | -13.03% | -12.03% | -3.08% | 13.85% | 23.81% |
| Normalized Diluted EPS | -13.04% | -12.15% | -5.56% | 11.97% | 21.89% |
| Average Basic Shares Outstanding | 2.72% | 3.61% | 4.14% | 4.62% | 5.23% |
| Average Diluted Shares Outstanding | 2.72% | 3.61% | 4.14% | 4.62% | 5.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |